MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | MicrobiomeTrials← Back to trialsNCT04032626
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2020-07-22Est. Completion: 2025-05-31
Enrollment target: 15 participants Locations- St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- Cleveland Clinic Lou Ruvo Center for Brain health, Las Vegas, Nevada, United States
Other microbiome trials you might be interested in
Moderate to Severe Alzheimer's Disease
The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients wit…
Multiple LocationsEst. completion Jan 2028
Emergency Department PatientComfort
Introduction: The aging of the population is a global phenomenon, with projections indicating a significant increase in …
São Paulo, BrazilEst. completion Mar 10, 2027
Recruiting
Patients With SynucleinopathiesNeurogenic Orthostatic HypotensionPure Autonomic FailureREM Sleep Behavior DisorderParkinson DiseaseDementia With Lewy BodiesMultiple System AtrophyShy-Drager Disease
Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumula…
Boston, United StatesEst. completion Dec 30, 2026